List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Seborrhea - Overview
Seborrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Seborrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Seborrhea - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arcutis Inc
Cutanea Life Sciences Inc
DermBiont Inc
Vyome Therapeutics Inc
Seborrhea - Drug Profiles
ARQ-154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Seborrhea - Dormant Projects
Seborrhea - Discontinued Products
Seborrhea - Product Development Milestones
Featured News & Press Releases
Jun 22, 2020: Arcutis enrolls last patient in phase 2 proof of concept clinical trial evaluating ARQ-154 (Topical Roflumilast Foam) as a potential treatment for Seborrheic Dermatitis
Dec 05, 2019: Arcutis announces ARQ-154 program for seborrheic dermatitis and enrollment of first patient in phase 2 proof of concept clinical trial
Feb 28, 2019: Aclaris Therapeutics Receives European Approvals of ESKATA (hydrogen peroxide) cutaneous solution, 685 mg
Dec 18, 2018: Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
Oct 01, 2018: Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA (hydrogen peroxide) Topical Solution 40%, (w/w)
Jun 12, 2018: Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris ESKATA is safe and effective in treating persons with raised seborrheic keratoses
May 30, 2018: Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA
May 16, 2018: Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
May 07, 2018: Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)
Feb 08, 2018: Aclaris Therapeutics to Present Data on ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
Dec 15, 2017: Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
Sep 19, 2017: Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aug 03, 2017: Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
Jun 13, 2017: Aclaris Therapeutics Announces Issuance of New US Patent For A-101 Topical Solutions
May 09, 2017: FDA Accepts Aclaris Therapeutics' New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Seborrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2020
Seborrhea - Pipeline by Arcutis Inc, H2 2020
Seborrhea - Pipeline by Cutanea Life Sciences Inc, H2 2020
Seborrhea - Pipeline by DermBiont Inc, H2 2020
Seborrhea - Pipeline by Vyome Therapeutics Inc, H2 2020
Seborrhea - Dormant Projects, H2 2020
Seborrhea - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Seborrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Aclaris Therapeutics Inc
• Arcutis Inc
• Cutanea Life Sciences Inc
• DermBiont Inc
• Vyome Therapeutics Inc